tetano
Editor, Senior Moderator
ACS Biomater Sci Eng
. 2023 Feb 28.
doi: 10.1021/acsbiomaterials.2c00669. Online ahead of print.
Safety and Biodistribution of Nanoligomers Targeting the SARS-CoV-2 Genome for the Treatment of COVID-19
Colleen R McCollum[SUP] 1 [/SUP], Colleen M Courtney[SUP] 1 2 [/SUP], Nolan J O'Connor[SUP] 1 [/SUP], Thomas R Aunins[SUP] 1 [/SUP], Tristan X Jordan[SUP] 3 [/SUP], Keegan L Rogers[SUP] 4 [/SUP], Stephen Brindley[SUP] 4 [/SUP], Jared M Brown[SUP] 4 [/SUP], Prashant Nagpal[SUP] 2 5 [/SUP], Anushree Chatterjee[SUP] 1 2 5 [/SUP]
Affiliations
Abstract
As the world braces to enter its fourth year of the coronavirus disease 2019 (COVID-19) pandemic, the need for accessible and effective antiviral therapeutics continues to be felt globally. The recent surge of Omicron variant cases has demonstrated that vaccination and prevention alone cannot quell the spread of highly transmissible variants. A safe and nontoxic therapeutic with an adaptable design to respond to the emergence of new variants is critical for transitioning to the treatment of COVID-19 as an endemic disease. Here, we present a novel compound, called SBCoV202, that specifically and tightly binds the translation initiation site of RNA-dependent RNA polymerase within the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome, inhibiting viral replication. SBCoV202 is a Nanoligomer, a molecule that includes peptide nucleic acid sequences capable of binding viral RNA with single-base-pair specificity to accurately target the viral genome. The compound has been shown to be safe and nontoxic in mice, with favorable biodistribution, and has shown efficacy against SARS-CoV-2 in vitro. Safety and biodistribution were assessed using three separate administration methods, namely, intranasal, intravenous, and intraperitoneal. Safety studies showed the Nanoligomer caused no outward distress, immunogenicity, or organ tissue damage, measured through observation of behavior and body weight, serum levels of cytokines, and histopathology of fixed tissue, respectively. SBCoV202 was evenly biodistributed throughout the body, with most tissues measuring Nanoligomer concentrations well above the compound K[SUB]D[/SUB] of 3.37 nM. In addition to favorable availability to organs such as the lungs, lymph nodes, liver, and spleen, the compound circulated through the blood and was rapidly cleared through the renal and urinary systems. The favorable biodistribution and lack of immunogenicity and toxicity set Nanoligomers apart from other antisense therapies, while the adaptability of the nucleic acid sequence of Nanoligomers provides a defense against future emergence of drug resistance, making these molecules an attractive potential treatment for COVID-19.
Keywords: COVID-19; RNA-dependent RNA polymerase; antisense therapy; biodistribution; safety.
. 2023 Feb 28.
doi: 10.1021/acsbiomaterials.2c00669. Online ahead of print.
Safety and Biodistribution of Nanoligomers Targeting the SARS-CoV-2 Genome for the Treatment of COVID-19
Colleen R McCollum[SUP] 1 [/SUP], Colleen M Courtney[SUP] 1 2 [/SUP], Nolan J O'Connor[SUP] 1 [/SUP], Thomas R Aunins[SUP] 1 [/SUP], Tristan X Jordan[SUP] 3 [/SUP], Keegan L Rogers[SUP] 4 [/SUP], Stephen Brindley[SUP] 4 [/SUP], Jared M Brown[SUP] 4 [/SUP], Prashant Nagpal[SUP] 2 5 [/SUP], Anushree Chatterjee[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 36853144
- DOI: 10.1021/acsbiomaterials.2c00669
Abstract
As the world braces to enter its fourth year of the coronavirus disease 2019 (COVID-19) pandemic, the need for accessible and effective antiviral therapeutics continues to be felt globally. The recent surge of Omicron variant cases has demonstrated that vaccination and prevention alone cannot quell the spread of highly transmissible variants. A safe and nontoxic therapeutic with an adaptable design to respond to the emergence of new variants is critical for transitioning to the treatment of COVID-19 as an endemic disease. Here, we present a novel compound, called SBCoV202, that specifically and tightly binds the translation initiation site of RNA-dependent RNA polymerase within the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome, inhibiting viral replication. SBCoV202 is a Nanoligomer, a molecule that includes peptide nucleic acid sequences capable of binding viral RNA with single-base-pair specificity to accurately target the viral genome. The compound has been shown to be safe and nontoxic in mice, with favorable biodistribution, and has shown efficacy against SARS-CoV-2 in vitro. Safety and biodistribution were assessed using three separate administration methods, namely, intranasal, intravenous, and intraperitoneal. Safety studies showed the Nanoligomer caused no outward distress, immunogenicity, or organ tissue damage, measured through observation of behavior and body weight, serum levels of cytokines, and histopathology of fixed tissue, respectively. SBCoV202 was evenly biodistributed throughout the body, with most tissues measuring Nanoligomer concentrations well above the compound K[SUB]D[/SUB] of 3.37 nM. In addition to favorable availability to organs such as the lungs, lymph nodes, liver, and spleen, the compound circulated through the blood and was rapidly cleared through the renal and urinary systems. The favorable biodistribution and lack of immunogenicity and toxicity set Nanoligomers apart from other antisense therapies, while the adaptability of the nucleic acid sequence of Nanoligomers provides a defense against future emergence of drug resistance, making these molecules an attractive potential treatment for COVID-19.
Keywords: COVID-19; RNA-dependent RNA polymerase; antisense therapy; biodistribution; safety.